Literature DB >> 10868299

[In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].

Y Yamashiro1, N Ogake, M Takahata, S Minami.   

Abstract

The in vitro interactions of piperacillin (PIPC) and imipenem/cilastatin (IPM/CS) combined with 5 kinds of aminoglycosides (gentamicin, tobramycin, amikacin (AMK), isepamicin and netilmicin) were investigated against IPM/CS-susceptible (MIC of IPM/CS was < or = 3.13 micrograms/ml) and IPM/CS-resistant (MIC of IPM/CS was > or = 12.5 micrograms/ml) Pseudomonas aeruginosa. The following results were obtained. 1. In the checkerboard dilution studies, the combinations of PIPC with aminoglycosides showed synergistic effect for more than 50% of the each 54 strains of IPM/CS-susceptible and IPM/CS-resistant P. aeruginosa. The synergistic/additive effects of PIPC with aminoglycosides were demonstrated for all tested strains. 2. In the checkerboard dilution studies, the combinations of IPM/CS with aminoglycosides showed no antagonism against any strains. The synergistic effects of IPM/CS with aminoglycosides were demonstrated for 0 to 14.8%, and these values were smaller than the combinations of PIPC with aminoglycosides. 3. Corresponding to the results of checkerboard dilution studies, the combination of PIPC with AMK was more effective than the combination of IPM/CS with AMK on the killing curve for IPM-resistant P. aeruginosa. In conclusion, PIPC showed the synergistic effects in combinations with aminoglycosides against IPM/CS-resistant P. aeruginosa. These results suggest that the combination therapies of PIPC with aminoglycosides are useful for the clinical treatment of serious infections due to P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10868299

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  3 in total

1.  Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.

Authors:  Rajbharan Yadav; Jürgen B Bulitta; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Authors:  Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model.

Authors:  Jessica R Tait; Hajira Bilal; Kate E Rogers; Yinzhi Lang; Tae-Hwan Kim; Jieqiang Zhou; Steven C Wallis; Jürgen B Bulitta; Carl M J Kirkpatrick; David L Paterson; Jeffrey Lipman; Phillip J Bergen; Jason A Roberts; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antibiotics (Basel)       Date:  2022-01-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.